David Bredt - 15 Dec 2025 Form 4 Insider Report for Rapport Therapeutics, Inc. (RAPP)

Role
Chief Scientific Officer
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol
RAPP
Transactions as of
15 Dec 2025
Net transactions value
-$255,130
Form type
4
Filing time
16 Dec 2025, 17:07:08 UTC
Previous filing
18 Nov 2025
Next filing
05 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bredt David Chief Scientific Officer RAPPORT THERAPEUTICS, INC., 99 HIGH STREET, SUITE 2100, BOSTON /s/ Troy Ignelzi, Attorney-in-Fact 16 Dec 2025 0002022087

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RAPP Common Stock Sale $230,711 -7,704 -1.9% $29.95 393,438 15 Dec 2025 Direct F1, F2
transaction RAPP Common Stock Sale $24,419 -796 -0.2% $30.68 392,642 15 Dec 2025 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.58 to $30.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.61 to $30.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.